Praxis Precision Medicines Inc Ordinary Shares PRAX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PRAX is a good fit for your portfolio.
News
-
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
-
Praxis Precision Medicines to Participate in Upcoming April Conferences
-
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
-
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
-
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
-
Praxis Precision Medicines to Host PRAX-628 Program Update
-
Thinking about buying stock in Praxis Precision Medicines, Safety Shot, Catalyst Pharmaceuticals, Adicet Bio, or Exscientia?
Trading Information
- Previous Close Price
- $53.39
- Day Range
- $51.23–52.93
- 52-Week Range
- $12.60–66.46
- Bid/Ask
- $51.62 / $52.11
- Market Cap
- $885.15 Mil
- Volume/Avg
- 41,318 / 199,123
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 142.05
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 82
- Website
- https://www.praxismedicines.com
Comparables
Valuation
|
Metric
|
PRAX
|
PLRX
|
CBAY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 6.65 | 1.79 | 12.65 |
Price/Sales | 142.05 | 525.49 | 111.01 |
Price/Cash Flow | — | — | — |
Price/Earnings
PRAX
PLRX
CBAY
Financial Strength
|
Metric
|
PRAX
|
PLRX
|
CBAY
|
|---|---|---|---|
Quick Ratio | 5.16 | 17.43 | 10.70 |
Current Ratio | 5.39 | 17.72 | 10.96 |
Interest Coverage | — | −145.34 | −5.27 |
Quick Ratio
PRAX
PLRX
CBAY
Profitability
|
Metric
|
PRAX
|
PLRX
|
CBAY
|
|---|---|---|---|
Return on Assets (Normalized) | −90.85% | −22.68% | −30.06% |
Return on Equity (Normalized) | −122.22% | −24.50% | −51.97% |
Return on Invested Capital (Normalized) | −117.83% | −28.46% | −30.87% |
Return on Assets
PRAX
PLRX
CBAY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dzbvmbthzd | Hpzs | $559.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jjkbxbrz | Gqwmt | $102.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ntwnxjvg | Rswtc | $98.6 Bil | |
MRNA
| Moderna Inc | Rmmpjtfk | Bzwb | $41.0 Bil | |
ARGX
| argenx SE ADR | Dsbhpdwqy | Gcvxw | $22.6 Bil | |
BNTX
| BioNTech SE ADR | Hmjwwlrk | Pbvlg | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zgtljygl | Yjwkcz | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qkzrfzzvg | Yvqpn | $17.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gczlktsbg | Gctnz | $12.6 Bil | |
INCY
| Incyte Corp | Rgqhnhpt | Jfbfqx | $12.0 Bil |